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Introduction: In systemic endotoxaemia, bacterial lipopolysaccharide causes the rapid expression of tissue factor
(TF) and disseminated intravascular coagulation and in animal models, anticoagulants limit pathology and
promote survival. Recent studies have emphasised the importance of TF expressed by mononuclear cells for
initiating thrombin generation during endotoxaemia and suggested that endothelial cell TF is of little relevance.
However, the precise importance of endothelium for intravascular thrombin generation has not been established.
In this study, we compared the effect of equivalent levels of hirudin tethered to either endothelium or platelets
and monocytes.
Materials and Methods: CD31-Hir-Tgmice express a vesicle-targeted, membrane-tethered hirudin fusion protein
on endothelium, platelets and monocytes. Bone marrow chimeras between these mice and C57BL/6 were
generated The level of intravascular hirudin expressed during endotoxaemiawas quantiﬁed by inhibition studies
using an anti-hirudin antibody and reference to the circulating thrombin anti-thrombin complexes generated in
control mice given soluble hirudin.
Results and Conclusions:Antibody inhibition studies indicated that individual chimeras expressed similar levels of
hirudin fusion protein on endothelium alone as on platelets and leukocytes combined and accordingly, the levels
of thrombin anti-thrombin complexes and ﬁbrinogen in each chimera were similar, indicating equivalent
inhibition of thrombin generation. However, mice with hirudin on endothelium alone developed signiﬁcantly
less thrombocytopenia. These results suggest a hitherto unrecognized role of endothelium in thrombin-
dependent platelet sequestration during endotoxaemia. The data have implications for the development of
therapeutic strategies based on targeted anticoagulation to limit disseminated intravascular coagulation.
© 2013 Elsevier Ltd. All rights reserved.
Introduction
In systemic endotoxaemia induced by lipopolysaccharide (LPS),
widespread intravascular activation of coagulation by tissue factor (TF)
is a critical early pathophysiological event. For that reason, inhibiting
either the initiation or propagation phases of clotting [1–8] has a
signiﬁcant impact on morbidity and mortality in experimental models.
The mechanisms that trigger intravascular coagulation in endo-
toxaemia have been studied in depth. TF is important for the initiation
phase of coagulation [9], but the source of TF has been controversial.
One hypothesis places the pathological activation of the vascular
endothelium, by the direct effects of LPS, at the heart of this process
[10]. In vitro, endothelial cell (EC) activation by LPS or inﬂammatory
cytokines such as TNFα, results in the expression of TF [11]. However,
EC expression of TF has never been convincingly demonstrated in vivo,
as discussed by Aird [12].
A second hypothesis with widespread support emphasises the im-
portance of LPS-activated leukocytes and platelets. Leukocyte-derived
TF includes the classical membrane-tethered moiety on activated cells
(reviewed in [13]) which has been shown to promote thrombosis
in vivo in one model of intravascular thrombosis [14]. TF is also found in
the alpha granules of platelets [15] and can also be found in blood in
the form of leukocyte- or platelet-derived microparticles [15,16]. These
can initiate clotting after P-selectin-mediated transfer of the TF to
activated platelet [17] or leukocyte membranes [18,19] and levels in the
blood correlate strongly with the amount of thrombin generated in
endotoxaemic mice [20]. A third form of TF, alternatively spliced and
lacking a transmembrane sequence has also been described. This soluble
protein, produced by CD14+monocytes, has procoagulant activity in the
presence of activated platelets [21].
Recent studies using mice expressing either low levels of TF, human
TF or strains in which TF has been selectively deleted from speciﬁc cell
types, have emphasised that TF expressed by non- haematopoietic
elements appears as important as that expressed by bone-marrow-
derived elements, in particular by monocytes [22]. However, selective
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knockout of TF on endothelium or smooth muscle cells appears to have
no impact on thrombin generation during LPS endotoxaemia [23].
Therefore, the non-haematopoietic source of TF remains uncertain, al-
though these studies suggest that it is not expressed by cells in the
vessel wall.
Only a fraction of the circulating factor IX (FIX) and factor X (FX) are
converted to their active forms, FIXa and FXa by TF during initiation of
coagulation [24]. In the absence of the activated cofactor factor Va, FXa
generates barely detectable levels of thrombin. Although insufﬁcient to
initiate signiﬁcantﬁbrin polymerization alone, trace amounts of thrombin
formed are able to back-activate intrinsic pathway cofactors factor V and
VIII, ultimately generating much larger amounts of thrombin which are
sufﬁcient to generate a clot. This ‘propagation’phase of coagulation occurs
onplasmamembranes and is dependent on the exposure of procoagulant
phospholipids [25]. A substantial body of data supports the idea that the
activated platelet membrane is an important site of thrombin generation
(see for instance, [26]). However, platelets appear not to be required for
ﬁbrin generation in a vessel injury model in mice [27].
Activated EC may also contribute to the generation of thrombin, but
much less is known about the involvement of EC membranes in this
process in vivo. However, activated EC lose many of their anticoagulant
functions (reviewed in [28]), consequent upon the downregulation of
thrombomodulin expression [29,30], and shedding of endothelial cell
protein C receptor (ePCR) [31] along with surface glycosaminoglycans
with resultant loss of non-covalently bound molecules such as anti-
thrombin and tissue factor pathway inhibitor [32]. Some of these
changes have been observed in vivo during sepsis [33], indicating their
potential relevance.
The series of experiments reported here addresses the relative
importance of activated EC, platelets and monocytes for thrombin
inhibition during LPS endotoxaemia. We have used transgenic mice ex-
pressing the leech anticoagulant hirudin as a stable, covalently linked
membrane fusion protein to inhibit thrombin on these surfaces. In
previous work, we showed that EC expression was sufﬁcient to inhibit
the development of consumptive coagulopathy after LPS [34]. In this
study, we show that expression of the hirudin fusion protein on
platelets and leukocytes appears as efﬁcient at inhibiting thrombin as
when similar levels are expressed on EC. However, platelet expression
was accompanied by profound thrombocytopenia that was not seen
when the hirudin fusion protein was expressed on EC. These data
suggest that preventing procoagulant changes on activated EC has a
more signiﬁcant inﬂuence on pathology than on platelet or leukocyte
membranes, despite the fact that both appear effective at inhibiting
thrombin.
Materials and methods
CD31-Hir-Tg mice
Generation of thesemice, their characterisation and phenotype after
LPS injection have been described [34]. All mice in this study were
heterozygous and were backcrossed for at least 5 generations onto a
C57BL/6 (BL/6) background.
Immunohistochemistry
Organs were embedded in OCT (BDH, Lutterworth, UK) by freezing
with dry ice, sectioned and ﬁxed in methanol at –20°C. Frozen sections
were immersed in 1% BSA-PBS and 10% goat serum (Sigma, Poole
Dorset UK) for 30 min, then incubated overnight at 4 °C with one of
the following antibodies; sheep anti-hirudin, (Enzyme Research Lab.,
Swansea, UK), rabbit anti-mouse TF [35], FITC-conjugated rabbit anti-
human ﬁbrinogen, (DAKO, Glostrup, Denmark). Second layer staining
was with goat anti-rabbit IgG-FITC, donkey anti-sheep IgG-FITC or
sheep anti-mouse IgG-FITC (all from Sigma).
Cell lines
Immortalised porcine EC transfectants expressing hirudin fusion
protein have been described previously [36]. EC were maintained
in DMEM (Invitrogen, Paisley, UK) supplemented with 10% FCS
(Globepharm, Surrey, UK), penicillin, streptomycin, L-glutamine
and mycophenolic acid.
Leukocyte isolation
Mouse blood, collected by tail-tip resection, was diluted 1:20 in ACK
buffer (155 mM NH4Cl/10 mM KHCO3/0.1 mM EDTA). After 20 min at
room temperature, cells were washed and resuspended in 3%FCS/
DMEM medium. Monocyte phenotype was conﬁrmed with an anti-
mouse CD14 mAb (Pharmingen, San Diego, USA). Splenocytes were
isolated from homogenised mouse spleen, suspended in 10ml of ACK
buffer, incubated for 5 min at room temperature and re-suspended in
RPMI containing 10% FCS. Cells were activated with Conconavalin A at
the ﬁnal concentration of 5 μg/ml for 48hours at 37 °C.
Puriﬁcation of platelets
Platelet-rich plasma was obtained from blood by centrifugation at
80g for 10min, followed by dilution 1 in 20with 1% ammoniumoxalate
(Sigma) and 2.5mMof Gly-Pro-Arg-Pro peptide (Sigma). Samples were
placed in a counting chamber in amoist petri dish, allowed to settle and
the platelets in 1mm2 counted (=N). The number of platelets per litre
of blood= 2N× 109. Platelet phenotype was conﬁrmed with an anti-
CD41 mAb (Pharmingen).
Flow cytometry analysis
1×105 cells or platelets were incubated with primary antibodies for
30min on ice, followed by secondary antibodies for 30min. Antibodies
used were as described above. Stained cells were analysed on a
cytoﬂuorometer (Becton Dickinson, Franklin Lakes, USA).
In vitro clotting assay
Porcine EC transfectants expressing hirudin fusion protein were
included in a recalciﬁed mouse plasma clotting assay, similar to that
previously described [37]. The hirudin fusion protein variants expressed
by these clones lacked a cytoplasmic motif from P-selectin, so were
expressed constitutively at the cell membrane, avoiding the need for
activation and relocation, as would have been the case had primary
mouse EC been used [36]. Plasma was collected from BL/6 mice. EC
were seeded at a density of 105 cells/ml in a 6-well plate and grown
to near conﬂuence before addition of PMA for 12hours. After washing
three times with serum-free DMEM, cells were detached with EDTA
before a further wash. 5 × 106 EC were added to 200 μl of plasma,
recalciﬁed and the time to clot measured.
Endotoxic shock
All mice weighed 25g +/- 1 g. Experiments were performed under
terminal anaesthesia and conformed to UK national and institutional
guidelines. Mice were anaesthetized with 60 ng/g of sagatal (Rhone
Merieux Limited, Harlow, UK), and given a single injection of LPS
(Escherichia coli serotype 0127:B8 Sigma) 2mg/kg or saline (control)
intraperitoneally (IP). L-NAME (Alexis Corp., Nottingham, UK)
(50 mg/kg) was administered IP 30 min before LPS and again at
time 0, 2 and 4 hours post-LPS. This model was used to maximise
the thrombotic manifestations of endotoxin, as previously described
[34,38] during the short time-interval available whilst the mice were
under terminal anaesthesia. In some experiments, soluble hirudin
(Enzyme Research Labs) or anti-hirudin mAb were administered at
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variable doses with LPS. Mice were sacriﬁced 4.5 hours post-LPS or
saline and blood samples were withdrawn by puncture of the heart
into 0.1 volume of 3.8% sodium citrate (Sigma).
Bleeding time assay
Anaesthetised mice were maintained in a restrainer (Becton
Dickinson) and a distal 2-mm segment of tail was severed. The tail
was immersed in 0.9% saline at 37 °C. Bleeding time was deﬁned as
the time required for the bleeding to stop [39].
Fibrinogen assay
Fibrinogen levels were measured using the Clauss method with
bovine thrombin (Sigma). Assays were terminated at 20mins.
Bone marrow (BM) reconstitution
BM was ﬂushed from the excised ends of long bones from
euthanized mice and re-suspended at 5 × 107 cells/ml in fresh RPMI.
Recipient mice were irradiated with 1200 Rad, before injection of
1×107 BMcells into a tail vein.Micewere isolated for fourweeks before
further experimentation.
Determination of thrombin-antithrombin III (TAT) complexes
Blood was collected by tail-tip resection and centrifuged at 13000 g
for 10 mins at 4 °C to obtain platelet-poor plasma. TAT levels were
determined using a commercial ELISA-based kit (Enzygnost TAT, Dade
BehringAG, Germany) andmicrotiter plate reader (TitertekMultiskan®,
Labsystems, Finland) according to the manufacturer’s instructions. All
estimations were in triplicate.
Method to quantitate expression of hirudin fusion protein
The concentration of anti-hirudin mAb required to completely
inhibit the anticoagulant phenotype of 1×105 porcine EC transfectants
expressing hirudin-CD4 fusion protein in 1 ml of recalciﬁed mouse
plasma [37] was determined by titration. This amount of anti-hirudin
mAb was incubated with various concentrations of soluble hirudin in
1 ml for 60 min at room temperature. The mix was then added to
1× 105 transfectants and incubated for 30min on ice. Antibody bound
to the transfectants was analysed by ﬂow cytometry. The concentration
of soluble hirudin that reduced antibody binding to zero was taken as
the equivalent of that expressed by 1×105 transfectants
Results
Analysis of relative hirudin fusion protein expression in Tg mice and BM
chimeras
To enable a quantitative analysis of the amount of hirudin fusion
protein expressed by CD31-Hir-Tgmice, we ﬁrst characterised the effect
of soluble recombinant hirudin on parameters of coagulation in wild-
type BL/6 mice. In this way, a mathematical relationship between
hirudin and plasma thrombin anti-thrombin (TAT) in endotoxaemic
wild-type BL/6 mice was deﬁned (Fig. 1A). Data was analysed using
the regression analysis facility of Sigmaplot, and data ﬁt analysed by
R2 values. In this way, TAT levels in subsequent experiments could be
deﬁned in terms of an equivalent amount of hirudin given to wtBL/
6mice; we called this measure of TAT a “Hirudin Equivalent” (HEQ).
BM chimeras between CD31-Hir-Tg and wild-type BL/6 mice were
generated (‘BMHir-wtB6’ and BMwtB6-Hir mice) along with BMwtB6-
wtB6 and BMHir-Hir controls. TAT concentrations after injection of
LPS/L-NAME into these mice are shown in Table 1, along with HEQ
values derived from Fig. 1A.
To estimate the amount of functional hirudin in the BMHir-wtB6 and
BMwtB6-Hir mice, chimeras were injected with increasing con-
centrations of an anti-hirudin monoclonal antibody known to inhibit
thrombin binding. The TAT levels and their HEQs are shown in
Table 1. HEQ values from these experiments were plotted against the
dose of antibody, as shown in Fig. 1B. At the point on these curves
where 50% of HEQ activity was inhibited (=[HEQ]50%), the amount of
antibody administered is directly proportional to the concentration of
surface membrane-expressed hirudin fusion protein. As shown, this
concentration was almost identical in the two types of chimera,
indicating no signiﬁcant difference in the amount of functionally active
surface exposed hirudin fusion protein expressed in BMwtB6-Hir and
BMHir-wtB6 mice.
Inhibition of thrombin and parameters of DIC in BM chimeric mice
Although the TAT and ﬁbrinogen levels in the BMwtB6-Hir and
BMHir-wtB6 chimeric mice were not signiﬁcantly different at baseline
(Table 1), bleeding times and particularly platelet counts were
signiﬁcantly better in the BMwtB6-Hir compared to BMHir-wtB6 mice
(Table 2). HEQs derived from these three parameters (ﬁbrinogen,
bleeding times and platelet count) and plotted in a similar way to that
shown in Fig. 1B conﬁrmed no signiﬁcant difference between the
amount of anti-hirudin required to achieve [HEQ]50% in each of the
chimeras (5.43 ± 0.74 ng/g in BMwtB6-Hir vs. 4.43 ± 0.54 ng/g in
BMHir-wtB6. P=NS), conﬁrming similar levels of hirudin fusion protein
expression at cell surfaces in the two types of chimera.
To verify these data, we went back to samples collected from a
previous series of BM chimeras [34] and measured TAT levels. This
analysis was consistent with the data shown here (data not shown).
No evidence for enhanced potency of hirudin fusion proteins expressed
on EC
To address the theoretically possible (but biologically implausible)
explanation that a given amount of hirudin fusion protein gained
increased potency when expressed on EC membranes, in vitro ex-
periments using porcine EC transfectants were conducted.
The null hypothesis tested by these experiments was that EC-
expressed hirudin fusion proteinwould bemore potent than an equiva-
lent amount of soluble hirudin added alongside control (untransfected)
EC in in vitro clotting assays using recalciﬁed human plasma. A ‘cold
competition’ approach described above was used to determine the
amount of hirudin fusion protein antigen expressed by a ﬁxed number
of transfectants (equivalent to 80 ng of soluble hirudin). Next, clotting
time assays in small volumes of recalciﬁed human plasma were
performed. These results are shown in Fig. 1C.
Addition of 80 ng of soluble hirudin to control EC prolonged the
clotting time to a level that was indistinguishable to that observed
when transfected EC were used. In separate wells, saturating con-
centrations of anti-hirudin antibody reduced the clotting time back to
that seen with control EC. These results were inconsistent with the
null hypothesis and suggested that soluble hirudin and membrane-
expressed hirudin fusion protein were equipotent when present at
equivalent concentrations on the EC surface.
Pattern of TF expression in endotoxaemic mice
Organs harvested 4.5 hours after LPS/L-NAME injection were
compared to control animals that received saline. In both wtBL/6
(Fig. 2A) and CD31-Hir-Tg (not shown) saline-treated mice, TF was
found only in the adventitia of blood vessels. However, after LPS/L-
NAME, TF was detected intraluminally in both strains, located on the
luminal aspect of the vessel wall. By this analysis, the distribution of
TF expression appeared the same in wtBL/6 and CD31-Hir-Tg mice. No
quantitative analysis was undertaken. Monocytes and platelets from
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wtBL/6 and CD31-Hir-Tg saline-injected animals were negative for TF
whereas those from both types of LPS/L-NAME-treated mice stained
positive for TF (Fig. 2B). Monocytes and platelets from LPS/L-NAME
but not saline-treated CD31-Hir-Tg mice expressed the hirudin fusion
protein, detectable by ﬂow cytometry (data not shown).
Discussion
Animal studies have indicated TF-induced thrombin generation as a
critical event in the early pathophysiology of endotoxaemia and sepsis
and shown a signiﬁcant reduction inmorbidity andmortality in animals
administered anticoagulants. However in humans disappointing results
from phase III trials of anticoagulants have added to uncertainty about
the importance of coagulation and of the clinical role of coagulation
inhibitors [40–42].
One of the many difﬁculties with research in this ﬁeld up until
recently was a lack of understanding of the microanatomy and kinetics
of how coagulation is initiated and propagated in vivo. One school of
thought has the endothelium at the heart of the process but another
emphasises the importance of LPS-activated monocytes and activated
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Fig. 1.A:Relationship between plasmaTAT concentration ([TAT]) and administered dose of solublehirudin inwtBL/6mice. Each point is data derived from threemice. Error bars=SEM. R2
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platelet membranes. Much has been learned recently from the
intravital imaging of real-time clot formation in models of vascular
injury, particularly about the pathways of platelet activation, though
a key question remaining is where thrombin generation occurs [43]?
A related question concerns the biological signiﬁcance of anti-
coagulant modulation and shedding from EC membranes during EC
activation. There are two potential alternatives. First, anticoagulant
shedding by ECmight act as amechanism to protect against intravascular
thrombosis, by raising the plasma levels of circulating anticoagulants (as
has been observed for TFPI in sepsis [44] and EPCR in endotoxaemia [31]).
On the other hand, anticoagulant down regulation and shedding from the
EC surface might occur to promote intravascular clotting to promote
unregulated thrombin generation on the endothelium.
In this paper, we have used a strain of mice expressing a hirudin
fusion protein on activated EC, platelets and leukocytes under the
control of the CD31 promoter. As we have described elsewhere [34],
cell membrane surface expression was regulated by inclusion of a P-
selectin cytoplasmic sequence, which directed resting fusion protein
expression to secretory granules of CD31-positive cells.
Previously, we showed that these mice were resistant to the coagu-
lopathy that developed after injection of LPS/L-NAME and it was
apparent from bone marrow reconstitution studies that expression of
the fusion protein on EC alone was sufﬁcient to provide near-maximal
protection against LPS. One criticism of this early work was that we
did not exclude the possibility that a quantitative difference in the
amount of functional hirudin expressed by the different chimeras was
the reason for these results.
In this study, we have addressed this criticism. Our new data
suggest no quantitative difference between the amounts of hirudin
fusion protein expressed by the two chimeras. Importantly, having
shown this, we can state that there was equivalent inhibition of
thrombin when the hirudin fusion protein was expressed on either
endothelium alone or on platelets/leukocytes. However, the data
also indicates that the hirudin fusion protein had an enhanced
potency in vivo on EC membranes, particularly at inhibiting the
profound endotoxaemia-induced thrombocytopenia. Our accompanying
in vitro data suggests that soluble hirudin was equipotent to the fusion
protein when present at high concentrations in the proximity of the EC
membrane.
Immunohistology data suggested that TF-expressing LPS-activated
monocytes and platelets, which could be detected in the circulation,
were sequestered at the site of clot formation in endotoxaemia, placing
them in close proximity to the endothelium. There were no gross
differences in the patterns of intravascular TF between the different
mice used here. Therefore, our interpretation is that the enhanced effect
of the hirudin fusion protein on EC is because there is an important
interaction between endothelium and platelets during the propagation
phase of coagulation during endotoxaemia. This is consistent with what
has been shown during real-time imaging of thrombus formation after
vascular injury [45] and with data showing that endothelial secretion
of protein disulphide isomerase is more important than platelet
secretion forﬁbrin formation in vivoduring vascular injury, even though
activated platelets are recruited to the vessel wall [46].
The interaction between P-selectin and its ligand PSGL-1 is known to
be an important determinant of the thrombocytopenia that develops in
this model, which has been shown to be due to platelet sequestration
within pulmonary alveolar capillaries, involving platelet-expressed P-
selectin [47]. P-selectin is expressed on the surface of activated platelets
and endothelial cells during endotoxemia and thrombin is known to
enhance expression by both [48,49]. Our data, by indicating that direct
inhibition of thrombin on platelets is less efﬁcient than inhibition on
endothelial cells at preventing thrombin-dependent platelet seques-
tration, highlights the complexity of the platelet interaction with
endothelium in endotoxaemia. We have not addressed the kinetics of
TF expression and fusion protein-relocation to the membrane in each
of the three compartments studied, but think it unlikely that our results
are due to temporal differences, even if they do exist.
In interpreting this data, it is interesting to speculate why organisms
have evolved such a response to endotoxin, aswidespread intravascular
coagulation and thrombosis is inherently disadvantageous if it results in
multiple organ dysfunction and ultimately death. One possibility is that
it may bestow a survival advantage in animals that are in the early
stages of developing sepsis and exposed to low concentrations of
endotoxin. Alternatively, it may represent a ‘design ﬂaw’ in the inﬂam-
matory response to pathogens, tolerated because the physiological
clotting response is efﬁcient at preventing haemorrhage after vascular
injury. Evidence that heterozygous carriers of factor V Leiden mutation
have a distinct advantage in sepsis and endotoxaemia appears to
support the former of these two possibilities [50].
If generating thrombin during early sepsis endows a survival
advantage, the gain must be sufﬁciently signiﬁcant to justify risking
widespread intravascular thrombosis, infarction and organ failure during
the later stages of infection. The conventional explanation for why
intravascular thrombosis develops during sepsis is that ﬁbrin clots may
Table 1
Plasma TAT concentrations in bone marrow chimeras 4.5 hours after LPS/L-NAME injection.
BMwtB6-wtB6 BMHir-Hir BMwtB6-Hir BMHir-wtB6
Anti-Hir mAb (ng/g) [TAT]⁎ HEQ† [TAT]⁎ HEQ† [TAT]⁎ HEQ† [TAT]⁎ HEQ†
0 174 (±5) 4 84 (±3) 239 103 (±5) 97 113¶ (±4) 67
0.1 175 (±0.3) 4 84 (±0.3) 239 103 (±0.3) 97 113# (±0.3) 67
0.3 177 (±0.3) 3 84 (±0.3) 212 104 (±0.3) 94 115# (±0.3) 63
1 175 (±0.3) 4 87 (±0.3) 200 109 (±0.3) 78 119# (±0.3) 55
3 176 (±0.3) 3 89 (±0.3) 180 120 (±0.3) 53 132# (±0.3) 35
10 176 (±0.3) 3 103 (±0.3) 97 151 (±0.3) 17 163# (±0.3) 10
The hirudin equivalent (HEQ) values are derived from the data represented in Fig. 1A.Micewere injectedwith an inhibitorymonoclonal antihirudin antibody at time of LPS injection. Each
value is the mean of TAT concentrations estimated in triplicate from each of three individual mice.
⁎ [TAT] in ng/ml.
† HEQ in ng/g.
¶ p=NS compared to equivalent values in BMwtB6-Hir.
# P b 0.01 compared to equivalent values in BMwtB6-Hir.
Table 2
Plasma ﬁbrinogen, bleeding times and platelet counts in bonemarrow chimeras 4.5hours
after LPS/L-NAME injection.
BMwtB6-wtB6 BMHir-Hir BMwtB6-Hir BMHir-wtB6
Fibrinogen⁎ 3 (±0.4) 23 (±3) 18 (±2) 14¶ (±2)
Bleeding time (minutes) 19 (±3) 7 (±1) 9 (±1) 13# (±1)
Platelet count (x10-9/l) 19 (±3) 191 (±10) 173 (±7) 88† (±6)
Each value is the mean of triplicate estimations from each of three individual mice.
⁎ % ﬁbrinogen relative to control mouse (no LPS).
¶ P=NS compared to BMwtB6-Hir.
# P b 0.05 compared to BMwtB6-Hir.
† P b 0.01 compared to BMwtB6-Hir.
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serve to limit the spread of certain types of infection by isolating infected
tissue [51,52]. We have previously proposed another potential advan-
tage, based on activated clotting factor-mediated signalling through
protease-activated receptors on endothelial cells being required to
initiate local chemokine gradients for leukocyte recruitment [53]. We
speculate that any potential advantage will be lost in the CD31-Hir-Tg
mice, so understanding how these mice respond to infectious challenge
will be one focus of our future work.
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